Notícias

Hims & Hers Health (NYSE: HIMS) faces a demanding customer acquisition challenge to hit its 2026 revenue guidance amid rising churn risks tied to its oral Wegovy subscription model, Bank of America said. Analysts estimate HIMS would need to add approximately 225,000 new oral Wegovy...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The blended fair value estimate for Hims & Hers Health has moved from US$24.31 to US$26.82 per share, a change of around 10% in the latest update. That shift reflects a mix of more constructive views tied to the Novo Nordisk partnership and new product optionality, set against ongoing concerns around margins, regulation and execution that keep analyst opinions divided. As you read on, you will see how these moving pieces shape the evolving story and what to watch next in the analyst...

HIMS broadens beyond telehealth, adding labs, new hormone programs and global expansion as it builds a personalized care platform.

The launch follows Novo Nordisk’s failure to pay a C$250 patent maintenance fee in Canada.

Hims & Hers plunged 23% after a major Q1 earnings miss, but long-term growth stays intact via its Novo Nordisk GLP-1 partnership and a late 2026 expansion.

Hims & Hers has started offering eligible customers personalized treatment plans starting at $149/month

By Sriparna Roy May 21 (Reuters) - Hims & Hers Health said on Thursday it is now offering Canadians with type 2 diabetes a generic version of semaglutide, the active ingredient in Novo Nordisk's

The longevity industry is booming with high-tech tests, drugs, and medical devices. What to know for your health—and personal finances.

Hims & Hers Health’s first quarter was marked by a significant strategic pivot in its weight loss business, which management described as a move to prioritize branded medications over compounded products. CEO Andrew Dudum highlighted that this shift resulted in near-term financial pressures, including restructuring charges and margin compression, as the company adapted to evolving consumer demand and regulatory developments. The company also experienced increased investment in technology and ope

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peers.

Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.

Hims & Hers increased its private offering from $300 million to support expansion, Eucalyptus acquisition plans, and technology investment.

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.45%. June E-mini S&P futures (ESM26 ) fell -0.12%, and June E-mini Nasdaq futures...

Company says proceeds will support expansion and technology investments

Hims & Hers Tumbles as Convertible Note Deal Sparks Dilution Fears

The S&P 500 Index ($SPX ) (SPY ) today is down -0.20%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.57%. June E-mini S&P futures (ESM26 ) are down -0.28%, and June E-mini Nasdaq futures...

The S&P 500 Index ($SPX ) (SPY ) today is up +0.07%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.25%. June E-mini S&P futures (ESM26 ) are up +0.10%, and June E-mini Nasdaq futures...

Stock Drops Following Financing PlanShares of Hims & Hers Health (NYSE:HIMS) fell 7% on Monday after the company revealed plans to issue $300 million of convertible senior notes due in 2032 to qualified institutional investors. Company Targets Expansion and Infrastructure InvestmentHims & Hers said the proceeds from the offering are intended to maintain financial flexibility as it pursues its international growth strategy, including the proposed acquisition of Eucalyptus, which is expected to cl

Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector’s short history, and bargain hunters are circling the wreckage. But here’s what you should actually be watching. The Q1 2026 release on May 11, 2026 was a fracture. EPS came in ... Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss. Here Is the Profitable Healthcare Stock to Own Instead

Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing. That dislocation between share price and product progress is exactly the kind of setup retail investors should scan for: real revenue, real partnerships, and prices low enough that a successful ... 7 Healthcare AI Stocks Under $50 With Huge Upside Potential

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.

DOCS vs. HIMS: Which Stock Is the Better Value Option?

Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 3.8% year on year to $608.1 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $690 million at the midpoint, or 6% above analysts’ estimates. Its non-GAAP loss of $0.19 per share was significantly below analysts’ consensus estimates.

Hims & Hers faces profit pressure in first-quarter 2026, though subscribers increase and a Novo Nordisk GLP-1 partnership broadens weight-loss care.

Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

Hims & Hers continues growing rapidly, but shrinking margins and rising costs are beginning to test the company's long-term profitability story.

The stock continues to be very volatile.

Hims & Hers delivered a sharp earnings miss as GLP-1 and international expansion costs surged. Investors now face a classic tradeoff between near-term margins and long-term growth.

Hims & Hers Health (NYSE:HIMS) absorbed another analyst downgrade. Bank of America cut its price objective on Hims & Hers stock to $30 from $32, while keeping a Neutral rating. The firm called the recent results “a mixed quarter” and argued that the bar needs to come down before HIMS stock can work again. The ... BofA Cuts Hims & Hers Price Target as Mixed Quarter Resets Street Expectations